REVENUE RECOGNITION

3 Months Ended

Mar. 31, 2026

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

REVENUE RECOGNITION

a.     Net revenues

The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows:

	Three months ended March 31,				Year ended December 31,
	2026		2025		2025
United States	$	95,956	$	93,154	$	385,632
International markets:
Germany	24,504		18,718		79,407
France	22,878		17,859		76,189
Japan	10,243		8,709		37,786
Other international markets	15,679		11,937		56,898
International markets - Total	73,304		57,223		250,280
Greater China (1)	4,795		4,617		19,441
Total net revenues	$	174,055	$	154,994	$	655,353

(1) For additional information, see Notes 12 and 13 to the Consolidated Financial Statements in the 2025 10-K.

The Company's net revenues by performance period are as follows:

	Three months ended March 31,				Year ended December 31,
	2026		2025		2025
Net revenues recognized in the reporting period from performance obligations satisfied in:
Reporting period	$	164,435	$	144,418	$	632,358
Previous periods	9,620		10,576		22,995
Total net revenues	$	174,055	$	154,994	$	655,353

b.     Contract balances

The following table provides information about trade receivables, unbilled receivables and contract liabilities from contracts with customers:

	March 31, 2026		December 31, 2025
	Unaudited		Audited
Trade receivables	$	85,028	$	81,648
Unbilled receivables	$	8,246	$	7,787
Deferred revenues (short-term contract liabilities)	$	(15,912)	$	(15,948)

During the three months ended March 31, 2026 and 2025 and the year ended December 31, 2025 the Company recognized $15,948, $14,225 and $14,225, respectively, which were included in the deferred revenues (short-term contract liability) balance at January 1, 2026 and 2025.